Last reviewed · How we verify
IV Bisphosphonates
At a glance
| Generic name | IV Bisphosphonates |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE) (PHASE3)
- Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (PHASE1, PHASE2)
- Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta (PHASE3)
- Romosozumab Use to Build Skeletal Integrity (PHASE4)
- Preserving Geriatric Muscle With an Osteoporosis Medication (PHASE4)
- Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) (PHASE4)
- Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (PHASE2)
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Bisphosphonates CI brief — competitive landscape report
- IV Bisphosphonates updates RSS · CI watch RSS
- Amgen portfolio CI